PetIQ, Inc. Provides Revenue Guidance for the Second Quarter, First Half and Full Year 2022
May 04, 2022 at 04:05 pm EDT
Share
PetIQ, Inc. provided revenue guidance for the second quarter, first half and full year 2022. For the second quarter of 2022 the Company expects Net sales of approximately $260 million compared to $271 million of net sales in the second quarter of 2021.
For the first half of 2022 the Company expects pro forma net sales to increase approximately 9.0% compared to the first half of 2021.
For the full year 2022 the Company expects Net sales of approximately $985 million representing an increase of 5.6% compared to 2021.
PetIQ, Inc. is a pet medication and wellness company, which provides veterinary products and services. The Company operates through two segments: Products and Services. Products segment manufactures and distributes pet medication and health and wellness products to major United States retail and e-commerce channels through more than 60,000 points of distribution. It is focused its offerings on value-branded products, and third-party branded products for dogs and cats, including pet Rx medications, OTC medications, and wellness products. Services segment provides a comprehensive suite of services at approximately 2,600 community clinic locations and wellness centers hosted at retailers across 39 states. The segmentâs services include diagnostic tests, vaccinations, prescription medications, microchipping, grooming and hygiene and wellness checks. The Rx pet medications products include flea and tick control, heartworm preventatives, arthritis, thyroid, and other specialty medications.
PETIQ, INC. 
